English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, October 11, 2023
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
Wednesday, October 4, 2023
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
Thursday, September 28, 2023
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
Monday, September 25, 2023
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Thursday, September 21, 2023
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
Tuesday, September 12, 2023
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
Friday, August 4, 2023
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の構成銘柄に22年連続で選定
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
Thursday, July 20, 2023
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023(AAIC2023)において発表
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575